The evolution of progesterone receptor ligands

Progesterone is one of the first nuclear receptor hormones to be described functionally and subsequently approached as a drug target. Because progesterone (1) affects both menstruation and gestation via the progesterone receptor (PR), research aimed at modulating its activity is usually surrounded b...

Full description

Saved in:
Bibliographic Details
Published in:Medicinal research reviews 2007-05, Vol.27 (3), p.374-400
Main Authors: Madauss, Kevin P., Stewart, Eugene L., Williams, Shawn P.
Format: Article
Language:English
Subjects:
Contraceptives, Oral - therapeutic use
Furans - metabolism
Humans
Indoles - metabolism
Ligands
Models, Molecular
nuclear receptor
Oxazines - metabolism
progesterone
progesterone receptor
Progestins - antagonists & inhibitors
Progestins - metabolism
Progestins - therapeutic use
Quinolines - metabolism
Receptors, Progesterone - metabolism
steroid receptor
Steroids - metabolism
Steroids - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Progesterone is one of the first nuclear receptor hormones to be described functionally and subsequently approached as a drug target. Because progesterone (1) affects both menstruation and gestation via the progesterone receptor (PR), research aimed at modulating its activity is usually surrounded by controversy. However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug‐like steroids that mimic the gestational properties of progesterone; (2) drug‐like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non‐steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications. Although the latter have yet to see widespread clinical applications, their development is founded on a half century of research, and they represent the future for this drug target. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 3, 374–400, 2007
ISSN:0198-6325
1098-1128
DOI:10.1002/med.20083